Search
SOLACI Congress
HomePeripheral vascular diseaseFemoropopliteal

Femoropopliteal

View Category

Coronary disease

Arterial Patency in Femoropopliteal Disease with Drug-Eluting Balloons

Follow-up of drug-coated balloon angioplasty in femoropopliteal disease in a real-world population. Using drug-releasing devices has decreased the...
solaci -
Learn More
Femoropopliteal

Stent Revascularization in Femoropopliteal Disease: An Analysis of Clustered Randomized Trials

A study compared pooled data of claudication and critical ischemia patients treated with stenting vs. by-pass surgery...
solaci -
Learn More
Femoral

What Is the Best Strategy for Moderately Complex Femoropopliteal Lesions?

At present, PCI is the preferred treatment for femoropopliteal lesions and drug coated balloons (DCB) have shown...
solaci -
Learn More
Coronary disease

IN.PACT Study | Should We Start Using DCBs More Frequently in Cases of Femoropopliteal Disease?

With the new devices (drug-eluting balloons , drug-eluting stents , and atherotomes) percutaneous treatment is becoming the...
solaci -
Learn More
Femoropopliteal

Safety of Atherectomy in Femoropopliteal Disease

Peripheral artery disease hinders patient quality of life extensively. In advanced stages, such as critical lower limbs...
solaci -
Learn More
Femoropopliteal

Drug Coated Balloons in Femoropopliteal Territory: Predictors of Failed Patency

Endovascular treatment in femoropopliteal territory has become the strategy of choice over time, with diverse devices; among...
solaci -
Learn More
Femoropopliteal

EMINENT Trial | Stent Eluvia vs BMS in Femoropopliteal Territory

Endovascular therapy in femoropopliteal territory has become the standard, mainly with self-expanding stents, aimed at preventing early...
solaci -
Learn More
Femoropopliteal

Results of the COMPARE Study After 2 Years: Low Dose vs. High Dose Paclitaxel-Coated Balloons

The development of new devices and techniques has expanded the range of patients who benefit from endovascular...
solaci -
Learn More

SOLACI is the reference organization for Latin American cardiovascular interventionism.

Last News

COILSEAL: Use of Coils in Percutaneous Coronary Intervention, Useful for Complication Management?

Dr. Omar Tupayachi - 0
The use of coils as vascular closing tool has been steadily expanding beyond its traditional role in neuroradiology into coronary territory, where it remains...

Treatment of In-Stent Restenosis in Small Vessels with Paclitaxel-Coated Balloons

Dr. Andrés Rodríguez - 0
Coronary artery disease (CAD) in smaller epicardial vessels occurs in 30% to 67% of patients undergoing percutaneous coronary intervention and poses particular technical challenges....

Contemporary Challenges in Left Atrial Appendage Closure: Updated Approach to Device Embolization

Dr. Juan Manuel Pérez - 0
Even though percutaneous left atrial appendage (LAA) closure is generally safe, device embolization – with 0 to 1.5% global incidence – is still a...

Institutional News

Watch Again: Pulmonary Embolism in 2025 — Risk Stratification and Novel Therapeutic Approaches

solaci - 0
Our webinar “Pulmonary Embolism in 2025: Risk Stratification and Novel Therapeutic Approaches” is now available to watch. The session took place on November 25,...

Watch Again: SELUTION – Sirolimus-Eluting Balloon for De Novo Coronary Lesions – New Evidence and Clinical Perspectives

solaci - 0
Our webinar “SELUTION: Sirolimus-Eluting Balloon for De Novo Coronary Lesions – New Evidence and Clinical Perspectives”, held on November 19, 2025 via Zoom with...

25/11 – SOLACI Webinar: Pulmonary Embolism in 2025 – Risk Stratification and Novel Therapeutic Approaches

solaci - 0
The Latin American Society of Interventional Cardiology invites you to participate in a new virtual scientific event titled “Pulmonary Embolism (PE) in 2025: Risk...

Access

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Terms of Use -Privacy Policy